MIRM 外汇新闻
Mirum Pharma Says EMBARK Phase 2b Study Evaluating LIVMARLI Fails To Meet Endpoints
Mirum Pharmaceuticals, Inc. (MIRM) announced Monday top-line results of the Phase 2 EMBARK study evaluating LIVMARLI (maralixibat) oral solution versus placebo given as an adjuvant therapy to Kasai surgery in patients with biliary atresia.
RTTNews
|
1016天前
